It is classified, based on the expression of oestrogen and progesterone receptors and human epidermal growth factor receptor 2 (HER2), into hormone receptor-positive, HER2-positive or triple-negative breast cancer (TNBC). Here, ERBB2 is linked to triple-negative breast carcinoma.